57 results
8-K
EX-99.2
AGIO
Agios Pharmaceuticals Inc
4 May 18
Results of Operations and Financial Condition
7:07am
metabolic enzyme Tissue, organ, system Gene therapies Diverse pathophysiology and disease phenotypes Genetic mutation(s) Biochemical defects Toxic … ) Biochemical defects Toxic or deficient metabolites
Creating a New Wave of Transformational Therapies Understanding and correcting the root cause of the disease
8-K
EX-99.1
AGIO
Agios Pharmaceuticals Inc
13 Jan 14
Regulation FD Disclosure
12:00am
Metabolite A
pool
Re-activate mutant enzyme
Enzyme 3
(bypassed)
Reroute/rebalance pathway
Block production of
toxic metabolites
Pyruvate Kinase (PK
S-1
EX-10.12
AGIO
Agios Pharmaceuticals Inc
10 Jun 13
IPO registration
12:00am
in or with respect to the Premises, nor generate, store or dispose of any oil, toxic substances, hazardous wastes, or hazardous materials (each … to the premises.
No flammable, toxic, or otherwise hazardous materials may be brought in or about the Building unless: (i) authorized by the Property
8-K
EX-10.1
AGIO
Agios Pharmaceuticals Inc
19 Sep 14
Entry into a Material Definitive Agreement
12:00am
, store or dispose of any oil, toxic substances, hazardous wastes, or hazardous materials (each a, “Hazardous Material”), or permit the same … public areas, loading docks or corridors leading to the premises.
No flammable, toxic, or otherwise hazardous materials may be brought in or about
8-K
EX-99.1
AGIO
Agios Pharmaceuticals Inc
15 Oct 14
Regulation FD Disclosure
12:00am
pool
Metabolite C pool
Enzyme 2*
(mutant)
Alternative Pathway
Pathway modulation:
Reduce toxic metabolites or bypass
metabolic defect